Form 4: Gilead Director Exercises Options, Sells Shares

Gilead Sciences Director Jeffrey Bluestone exercised stock options and sold 5,000 shares of common stock for $123.50 per share under a pre-arranged trading plan.

Summary

• Jeffrey Bluestone, a Director at Gilead Sciences, Inc. (GILD), engaged in two transactions on January 20, 2026, pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
• Bluestone exercised non-qualified stock options to acquire 5,000 shares of common stock at an exercise price of $67.45 per share.
• Immediately following the option exercise, Bluestone sold 5,000 shares of common stock at a price of $123.50 per share.
• After these transactions, Bluestone's direct beneficial ownership of common stock remained at 8,920 shares.
• The number of non-qualified stock options beneficially owned by Bluestone decreased by 5,000, leaving 4,665 options remaining.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it involves insider selling, the transaction was pre-planned under a 10b5-1 plan, which mitigates any negative signal typically associated with insider sales. It represents a routine liquidity event for the director.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled liquidity event rather than a discretionary sale based on new information.
• The director realized a profit from the option exercise and sale, with the sale price significantly higher than the exercise price.

Negatives

• An insider (Director) reduced their holdings of derivative securities (options) by 5,000 units.

Future Outlook

This Form 4 filing details specific insider transactions and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction by a director of a major pharmaceutical company. Such transactions, especially when conducted under a Rule 10b5-1 plan, are common for personal financial planning and typically do not reflect broader industry trends or specific company performance signals.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if pre-planned, slightly increases the float but is unlikely to have a significant impact on the company's valuation or investor confidence given its routine nature.

Key Dates

Recommendation

The filing details a routine insider transaction where a director exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan. This type of transaction is typically for personal liquidity or diversification and does not usually signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider activity.

Keywords

Gilead Sciences, GILD, SEC Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Jeffrey Bluestone, 10b5-1 Plan, Director